Their primary therapeutic actions include stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying to promote satiety, and acting on hypothalamic appetite centers to reduce hunger and caloric intake
However, like most therapies targeting metabolic pathways, they are not free of risks
n=15), compared to the ~0.4% increase in HbA1c seen post-GLP-1 discontinuation in the STEP-1 trial extension 2 of GLP-1 withdrawal
If you have missed several doses or need to pause your treatment for any reason, it's best to contact your healthcare provider
For the secondary outcomes, the hazard ratios were below the null value for myocardial infarction, ischaemic stroke, cardiovascular mortality, heart failure, and all cause mortality, but with wide confidence intervals that included the null